

## AngioDynamics Launches Improved Centros(R) Self-Centering Hemodialysis Catheter

### *New Centros Catheter Features an Enhanced Tip Design to Optimize Blood Flow*

ALBANY, N.Y., May 10, 2010 (BUSINESS WIRE) -- [AngioDynamics](http://www.angiodynamics.com) (NASDAQ:ANGO) announced today it has achieved the national launch of the newly redesigned Centros self-centering, chronic hemodialysis access catheter.

The Centros hemodialysis access catheter employs Curved Tip(TM) Catheter Technology that is designed to provide higher blood flow and lower recirculation. When it is placed in the lower portion of the superior vena cava, the Centros catheter's curved tips keep the ports of the catheter centered, away from the vein walls. This is intended to prevent clots from forming or fibrin sheathing in which a fibrous protein in the blood coats the catheter, eventually closing up the openings and compromising its function. The Centros catheter design features also include an improved, lower-profile fiber cuff to maximize tissue ingrowth for anchoring and for ease of removal.

"The Centros self-centering hemodialysis catheter represents a significant improvement over other products currently available in its class," said Robert Rossell, Senior Vice President and General Manager of AngioDynamics' Vascular Access Business Unit. "The Centros catheter meets an important clinical need and with the new design features we believe this catheter will provide physicians and patients with a tool designed for faster procedures requiring fewer interventions and greater overall performance."

The Centros catheter owes its key design elements to Stephen R. Ash, MD, FACP, a world renowned thought leader in the field of hemodialysis access. Preliminary study results presented by Dr. Ash indicate that the Centros catheter provides highly acceptable flow rates at modest negative pressure without deterioration in flow rate over seven weeks of use, even with tips positioned in the superior vena cava rather than within the atrium. Flow rate for the Centros catheter at the seven week follow-up point was 401mL/min, compared to the control group of competitive catheters at 348mL/min. (P value less than 0.05).

For more information on the Centros self-centering, chronic hemodialysis access catheter, visit the AngioDynamics Web site at <http://www.angiodynamics.com/products/centros>.

### **About AngioDynamics**

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at [www.angiodynamics.com](http://www.angiodynamics.com).

### **Safe Harbor**

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

**Company Contact:**

AngioDynamics, Inc.

D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608

[jgersuk@AngioDynamics.com](mailto:jgersuk@AngioDynamics.com)

or

**Investor Relations Contacts:**

EVC Group, Inc.

Doug Sherk/Jenifer Kirtland, 415-896-2005

[dsherk@evcgroup.com](mailto:dsherk@evcgroup.com)

[jkirtland@evcgroup.com](mailto:jkirtland@evcgroup.com)

or

**Media Contact:**

EVC Group, Inc.

Chris Gale/Steve DiMattia, 646-201-5431

[cgale@evcgroup.com](mailto:cgale@evcgroup.com)

[sdimattia@evcgroup.com](mailto:sdimattia@evcgroup.com)

Copyright Business Wire 2010